Evidence map›Paper›PMID 34347909›Full record

ArticleHematological oncology2021

Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis.

Christopher R D'Angelo, Walter Hanel, Yi Chen, Menggang Yu, David Yang, Ling Guo, Reem Karmali, Madelyn Burkart, Colleen Ciccosanti, Kevin David and 12 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 13 institutions in 1 country.

Christopher R D'AngeloFred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Walter HanelDepartment of Internal Medicine, Division of Hematology/Oncology, The Ohio State University Hospital, Columbus, Ohio, USA.
Yi ChenDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Menggang YuDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
David YangDepartment of Pathology, University of Wisconsin Carbone Cancer Center Madison, Wisconsin, USA.
Ling GuoThe James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Reem KarmaliRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0003-0984-4376
Madelyn BurkartRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Colleen CiccosantiDepartment of Internal Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Kevin DavidDivision of Hematology/Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
Zachary RischThe James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Carlos Murga-ZamalloaDepartment of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA.
Sumana DevataDepartment of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Ryan WilcoxDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-6420-0760
Malvi SavaniDivision of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA.
Elizabeth L CourvilleDepartment of Pathology, University of Virginia, Charlottesville, Virginia, USA.
Veronika BachanovaDepartment of Internal Medicine, Division of Hematology/Oncology, University of Minnesota, Minneapolis, Minnesota, USA.
Emma RabinovichDepartment of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA.
David PeaceDepartment of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA.
Fauzia OsmanDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Narendranath EpperlaThe James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-8216-3457
Vaishalee P KenkreDepartment of Pathology, University of Wisconsin Carbone Cancer Center Madison, Wisconsin, USA.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USUniversity of Illinois Chicago · USUniversity of Wisconsin–Madison · USNorthwestern University · USRutgers, The State University of New Jersey · USUniversity of Wisconsin Carbone Cancer Center · USMedical College of Wisconsin · USOhio State University Hospital · USUniversity of Arizona · USUniversity of Michigan · USUniversity of Minnesota · USUniversity of Nebraska Medical Center · USUniversity of Virginia · US

Funding

RESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2M
NHLBI NIH HHS 5T32HL007899-20NHLBI NIH HHS T32 HL007899
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma featuring overexpression of MYC and B-Cell Lymphoma 2 (double expressor lymphoma, DEL) is associated with poor outcomes. Existing evidence suggesting improved outcomes for DEL with the use of more intensive regimens than R-CHOP is restricted to younger patients and based on limited evidence from low patient numbers. We retrospectively evaluated the impact of intensive frontline regimens versus R-CHOP in a multicenter analysis across 7 academic medical centers in the United States. We collected 90 cases of DEL, 46 out of 90 patients (51%) received R-CHOP and 44/90 (49%) received an intensive regimen, which was predominantly DA-EPOCH-R. Treatment cohorts were evenly balanced for demographics and disease characteristics, though the intensive group had a higher lactate dehydrogenase (LDH, 326 vs. 230 U/L p = 0.06) and presence of B-symptoms (50% vs. 22%, p = 0.01) compared to the R-CHOP cohort. There was no difference in PFS (median 53 vs. 38 months, p = 0.49) or overall survival (67 vs. not reached months, p = 0.14) between the R-CHOP and intensive therapy cohorts, respectively. On multivariate analysis, intensive therapy was associated with a hazard ratio of 2.35 (95% CI 0.74-7.41), though this was not statistically significant. Additionally, a subgroup analysis of intermediate high-risk lymphoma defined by IPI ≥3 did not identify a difference in survival outcomes between regimens. We conclude that in our multi-center cohort there is no evidence supporting the use of intensive regimens over R-CHOP, suggesting that R-CHOP remains the standard of care for treating DEL.

Indexed as

AgedHumansLymphoma, Large B-Cell, DiffuseMiddle AgedTreatment Outcomedouble expressor lymphomainitial therapyretrospective clinical analysis

Identifiers

PMID34347909
PMCPMC10279769
OpenAlexW3187620104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.